Infarct size and long-term clinical outcomes of prasugrel vs. clopidogrel in patients with acute coronary syndrome undergoing coronary artery stenting: a prospective randomized study

Infarct size and long-term clinical outcomes of prasugrel vs. clopidogrel in patients with acute coronary syndrome undergoing coronary artery stenting: a prospective randomized study - Study on the inhibitory effect of antiplatelet drugs on myocardial damage in acute coronary syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000044193

Enrollment

Registered

2021-05-13

Start date

2014-08-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute coronary syndrome

Interventions

prasugrel 20 mg before emergency PCI clopidogrel 300 mg before emergency PCI

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Cases of stent implantation for acute coronary syndrome

Exclusion criteria

Exclusion criteria: Exclusion criteria were PCI without stenting, or final thrombolysis in myocardial infarction (TIMI) flow grade < 3.

Design outcomes

Primary

Measure	Time frame
The primary endpoint was survival free of MACE.	—

Secondary

Measure	Time frame
The secondary endpoint was the evaluation of infarct size defined as the area under the curve of troponin I.	—

Countries

Japan

Contacts

Public ContactTakayuki Yabe

Toho University Omori Medical Center Cardiology

takayuki.yabe@med.toho-u.ac.jp0337624151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026